Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520790 · ClinicalTrials.gov registry record · Phase 1
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03520790 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 36 participants.
The verdict
NCT03520790, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This research study is a two stage study which consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be evaluated. The randomized phase 2 study will evaluate the efficacy of paricalcitol when added to gemcitabine and nab-paclitaxel The drugs involved in this study are: * Paricalcitol * Gemcitabine * Nab-paclitaxel
Interventions
- OTHER Placebo
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Paricalcitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520790
The ClinicalTrials.gov registry entry for NCT03520790 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03520790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03520790 about?
NCT03520790 is a clinical study titled "Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer". This research study is a two stage study which consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a ...
What is the current status of trial NCT03520790?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-12-05. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT03520790?
The interventions under investigation include: Placebo (OTHER), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Paricalcitol (DRUG).
Who is sponsoring clinical trial NCT03520790?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.